“We have to be much more comprehensive in our guidance and counselling of these patients,” says Nima Etminan (University Medical Centre Mannheim, Mannheim, Germany), speaking to NeuroNews at the 2026 European Society of Minimally Invasive Neurological Therapy (ESMINT) congress (2–4 September, Marseille, France) to discuss the results of a recent meta-analysis on global brain aneurysm prevalence published in The Lancet Neurology.
According to Etminan, these new findings—particularly when considered in conjunction with prior data on subarachnoid haemorrhage incidence in JAMA Neurology—“put things into perspective” regarding how many patients with unruptured intracranial aneurysms should ultimately undergo interventional treatment. In this video, Etminan also advocates greater focus on an individual patient’s overall risk factors as well as their aneurysm-related risk factors.
